Tango Therapeutics Inc Stock Price, News & Analysis

Tango Therapeutics (NASDAQ: TNGX) announced that Adam Crystal, M.D., Ph.D., President of Research & Development, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 1:30pm ET.

The event will be live webcast via the company's Investors > Events & Presentations page on the day of the presentation, and a replay will be archived on the company's website for 90 days following the presentation.

Tango Therapeutics (NASDAQ: TNGX) announced that CEO Barbara Weber, M.D. will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, 4:30–4:55 PM GMT / 11:30–11:55 AM ET. The session will be available live via webcast under the "Events & Presentations" tab on the company's Investors page. A replay will be archived on the company's website for 90 days after the presentation.

Tango Therapeutics (NASDAQ: TNGX) reported Q3 2025 results and operational updates on Nov 4, 2025. Key clinical data include vopimetostat mPFS 7.2 months in 2L MTAP-del pancreatic cancer and a 49% ORR with mPFS 9.1 months in a 13‑histology MTAP-del cohort. Vopimetostat combination studies with Revolution Medicines’ RAS(ON) inhibitors are ongoing with initial data expected in 2026. TNG456 received FDA Orphan Drug Designation for malignant glioma. TNG260 showed a subgroup mPFS of 27 weeks in STK11mut/KRAS WT lung cancer. Financially, the company reported Q3 net income $15.9M and held $152.8M cash as of Sept 30, 2025, plus ~$212M net proceeds from an October 2025 financing that extends runway into 2028.

Tango Therapeutics (NASDAQ: TNGX) will report third quarter 2025 financial results on Tuesday, November 4, 2025 at 9:00 AM ET, to be released before the U.S. market open.

The company said it does not intend to hold a conference call with investors or analysts following the release.

Tango Therapeutics (Nasdaq: TNGX) priced an underwritten offering and a concurrent PIPE to raise approximately $225 million in gross proceeds. The offering includes 21,023,337 shares of common stock and pre-funded warrants to purchase up to 3,226,458 shares at a per-share price of $8.66 (pre-funded warrant price $8.659). Gross proceeds from the offering are expected to be about $210 million; the PIPE is selling 1,732,101 shares for about $15 million. The transactions are expected to close on or about October 24, 2025, subject to customary conditions.

Tango Therapeutics (NASDAQ: TNGX) reported positive Phase 1/2 data for vopimetostat (TNG462) in MTAP-deleted cancers dated October 23, 2025. Across 94 evaluable patients, the overall ORR is 27%, disease control rate 78%, and median PFS 6.4 months. In 2L MTAP-del pancreatic cancer (n=39 at active doses) ORR 25% and mPFS 7.2 months; company plans a ~300-patient global randomized pivotal trial in 2026 at the FDA-aligned dose 250 mg QD. A histology-agnostic cohort (excluding pancreatic, lung, sarcoma) showed ORR 49% and mPFS 9.1 months. Safety at 250 mg QD was generally tolerable; most common TRAEs were nausea, anemia, fatigue, dysgeusia, thrombocytopenia.

Tango Therapeutics (NASDAQ: TNGX) will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 in National Harbor, MD, Nov 5–9, 2025.

Presentations include the first clinical data for TNG260, a first‑in‑class CoREST inhibitor being evaluated in the dose‑expansion phase of a Phase 1/2 trial in combination with pembrolizumab. The trial is enrolling patients with STK11‑mutant/RAS wild‑type lung cancer (about ~10% of lung adenocarcinoma).

All three posters are scheduled for Friday, November 7, 2025 (9:00am–7:00pm EDT). Key abstracts: #561 (clinical Phase 1/2; presenter Salman R. Punekar, M.D.), #681 (TNG260 sensitization; presenter Leanne Ahronian, Ph.D.), and #1225 (MGAT1 inhibition overcoming STK11 immune evasion).

Tango Therapeutics (NASDAQ:TNGX) announced its upcoming participation in the 2025 Cantor Global Healthcare Conference. The company's President and CEO, Barbara Weber, M.D., will participate in a fireside chat on September 3, 2025, from 2:45-3:15 PM ET.

Investors can access the live webcast through the "Events & Presentations" section on the company's investor relations website. The presentation recording will remain available for 90 days following the event.

Tango Therapeutics (NASDAQ:TNGX) reported Q2 2025 financial results and pipeline updates. The company achieved key milestones in its clinical programs, including first patient dosing in two trials: a combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors and a Phase 1/2 trial of TNG456 for glioblastoma.

Financial highlights include $180.8 million in cash reserves expected to fund operations into Q1 2027. Q2 2025 showed revenue of $3.2 million, down from $7.8 million in Q2 2024, and a net loss of $38.9 million ($0.35 per share). The company's collaboration with Gilead will conclude its research portion early, resulting in $53.8 million revenue recognition in Q3 2025.